Translational Glycobiology in Human Health and Disease

Edited by:   Michelle Kilcoyne (Lecturer in Glycosciences National University of Ireland Galway Ireland), Lokesh Joshi (Director, Advanced Glycoscience Research Cluster and Leader, Glycoscience Group, NUI Galway, Ireland)
Imprint:   Academic Press Inc
Country of Publication:   United States
Dimensions:   Height: 235mm,  Width: 191mm, 
Weight:   450g
ISBN:   9780128196557
ISBN 10:   0128196556
Pages:   480
Publication Date:   15 December 2023
Audience:   Professional and scholarly ,  Undergraduate
Format:   Paperback
Publisher's Status:   Active

Dr. Michelle Kilcoyne is Lecturer in Glycosciences at the National University of Ireland Galway. Dr. Michelle Kilcoyne completed her PhD in analytical carbohydrate chemistry in the School of Chemistry at NUI Galway in 2004, specialising in structural analysis of bacterial polysaccharides. She then took up a postdoctoral position in Arizona State University where she further specialised in mass spectrometry and HPLC, as well as expanding her interests to mammalian glycosylation. She returned as a postdoctoral researcher to NUI Galway in 2007 working on industry-supported and European projects, developing high throughput platforms for carbohydrate profiling. In 2014 Dr. Kilcoyne was appointed Lecturer in Glycosciences, is currently a member of Discipline of Microbiology at NUI Galway and leads the Carbohydrate Signalling Group. She is the recipient of a Royal Society of Chemistry Analytical Chemistry Trust Fund Fellowship for 2018. Her main interests are in glycoanalytics, novel glycomics platform development and carbohydrate-mediated host-microbe interactions. Prof. Lokesh Joshi is Director of the Advanced Glycoscience Research Cluster and leader of the Glycoscience Group at NUI Galway, a Co-Director of CÚRAM, a medical device centre, and the Vice-President for Research at NUI Galway. His principal focus of research is in understanding the roles of glycans and lectins in health and diseases and developing novel technologies for glycomics. Prof. Joshi has been involved in two spin out companies, Arizona Engineered Therapeutics (AzERx) and Aquila Biosciences. The NIH and VC sources funded AzERx to develop peptide-based therapeutics for vascular applications and AzERx was acquired by Orthologic (Now Capstone Therapeutics) in 2006. Aquila Bioscience is a healthcare company working on various projects funded by EI, EU, European Defence Agency and private industries. Prof. Joshi is an SFI-Stokes Professor of Glycosciences and the Irish representative on European Universities Association’s Research Programme Working group.